Publications by authors named "Richard S Kaczmarski"
Article Synopsis
- Aberrant NF-κB activity is linked to the development and survival of multiple myeloma (MM) and various other cancers, yet no specific inhibitors have been approved clinically due to harmful side effects from existing drugs.
- Researchers have developed a new inhibitor called DTP3, which selectively targets a cancer-specific survival mechanism related to NF-κB, effectively killing MM cells without harming healthy ones.
- Preclinical studies show that DTP3 has favorable properties, including effectiveness against cancer, a long-lasting presence in the body, and no toxic effects, leading to its approval for clinical trials in cancer treatment.
